Abstract 1958P
Background
ADT is an established treatment for PCa, influencing different aspects of tumor biology. The study aimed to assess expression of EMT (E- and N-cadherins (cad)) and CSC (CD44, CD133) markers as well as androgen (AR) and estrogen (ERα, ERβ) receptors and transforming growth factor beta type II receptor (TβRII) (an EMT regulator) in localized PCa samples after ADT.
Methods
56 radical prostatectomy cases were analyzed. 15 of them had 3-6 months of ADT before surgery. Double immunofluorescent staining was used. For E-cad and CD44 staining intensity was assessed, for CD133 – presence of staining, for N-cad– weighed staining index (WSI) and for AR, ERα, ERβ and TβRII – total staining scores (TSS) per case.
Results
In the studied cohort expression of EMT and CSC markers didn’t differ significantly in cases after ADT and without it (pχ2=0.71 for CD133, pMann-Whitney>0,05 for all other markers), that may assume that at least at the early stage of PCa development short-term ADT doesn’t influence these phenotypes. AR and ER expression both in stroma and epithelium didn’t differ significantly, except for ERβ in cancer cells nuclei, that appeared to be higher after ADT (TSS 6.00 vs. 3.25, pMann-Whitney=0.042). Expression of TβRII appeared to be significantly higher for nuclear and lower for membranous staining in ADT cases (Mann-Whitney test, TSS 2.33 vs. 1.20, p=0.002 and 0 vs. 0.58, p<0.001, respectively). Only in ADT cases CD44 was significantly higher in CD133+ tumors, and N-cad WSI correlated with CD44 expression, while ERα in both stroma and cancer cells correlated with epithelial AR (r=0.55 and r=0.54, pSpearman<0,05), though these associations were not seen in cases without ADT. Also moderate direct correlation was seen between nuclear TβRII and E-cad (r=0.52, pSpearman<0,05). Markers expression in pre-ADT biopsies and their dynamic changes on ADT could not be assessed.
Conclusions
ADT influences TβRII and ERβ expression in cancer cells and also modulates EMT and CSC markers and regulators correlations, that may assume that though ADT alone is not sufficient to induce EMT or CSC phenotypes, it may modulate intra-tissue interactions of signaling cascades and alter cell responses to regulating signals.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
M. Puchinskaya.
Funding
Belarusian Republican Foundation for Fundamental Research, grants No. M14M-143, M19M-123.
Disclosure
M. Puchinskaya: Financial Interests, Personal, Invited Speaker: Roche.
Resources from the same session
2019P - Disparities in urothelial carcinoma (UC) drug approval: Contrasting North America and Europe
Presenter: Jose Tapia
Session: Poster session 13
2020TiP - SOGUG-NEOWIN: A phase II, open-label, multi-centre trial evaluating the efficacy and safety of erdafitinib (ERDA) monotherapy and ERDA and cetrelimab (CET) as neoadjuvant treatment in cisplatin-ineligible patients with muscle-invasive bladder cancer (MIBC) and FGFR gene alterations
Presenter: Yohann Loriot
Session: Poster session 13
2022TiP - Stereotactic treatment with neoadjuvant radiotherapy and enfortumab vedotin: A phase I/II study for localized, cisplatin ineligible, muscle invasive bladder cancer (STAR-EV)
Presenter: Tian Zhang
Session: Poster session 13
2024TiP - NETOS: A personalized approach of neoadjuvant therapy, including INCB099280 monotherapy and bladder preservation, for muscle-invasive urothelial bladder carcinoma (MIBC) with ctDNA monitoring
Presenter: Valentina Tateo
Session: Poster session 13